Next Article in Journal
ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis
Next Article in Special Issue
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma
Previous Article in Journal
Estrogen Receptors Alpha and Beta in Acute Myeloid Leukemia
Previous Article in Special Issue
Dual Targeting of the p38 MAPK-HO-1 Axis and cIAP1/XIAP by Demethoxycurcumin Triggers Caspase-Mediated Apoptotic Cell Death in Oral Squamous Cell Carcinoma Cells
 
 
Article
Peer-Review Record

Karyopherin-β1 Regulates Radioresistance and Radiation-Increased Programmed Death-Ligand 1 Expression in Human Head and Neck Squamous Cell Carcinoma Cell Lines

Cancers 2020, 12(4), 908; https://doi.org/10.3390/cancers12040908
by Masaharu Hazawa 1,†, Hironori Yoshino 2,*,†, Yuta Nakagawa 3, Reina Shimizume 3, Keisuke Nitta 3, Yoshiaki Sato 2, Mariko Sato 4, Richard W. Wong 1 and Ikuo Kashiwakura 2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2020, 12(4), 908; https://doi.org/10.3390/cancers12040908
Submission received: 3 March 2020 / Revised: 27 March 2020 / Accepted: 4 April 2020 / Published: 8 April 2020
(This article belongs to the Special Issue Head and Neck Cancers)

Round 1

Reviewer 1 Report

The author concluded that combination therapy of KPNB1 inhibition and radiation is promising strategy for patients with HNSCC. Study subject is important and timely. Manuscript is well readable. However, following points should be addressed to be acceptable for this Journal.

Major concerns
1) Figure 5: How contribute deltaNp63 and PUMA on the expression of PD-L1 expression. This Figure only showed parallel data.
2) Figure 3 (Line 250-262): TP63 contains two different promoters to drive two distinct isoform such as TP63 and deltaNp63. Here, it is unclear what relevance with PUMA between TP63 and deltaNp63. Is there no involvement of p53-PUMA axis?

Other concerns:
1) Basic information about PUMA and deltaNp63 should be described concisely in Introduction. Part of Discussion may be moved to Introduction.
2) Please show IC50 and treated dose of IPZ for A549 cells (Line 271, Figure 4).
3) Materials and Methods: Please indicate source of RERF-LC-MS and H1299 cell lines and their culture conditions.

Author Response

We are very glad that the reviewer feels that the study is important. We appreciate the reviewer’s comments and have tried our best to address the reviewer’s queries. All the changes have been highlighted in the revised manuscript. 

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

This is an interesting manuscript describing the effects of KPNB1 inhibitor, IPZ, or KPNB1 knockdown on radiation response in HNSCC cell lines, SAS and Ca9-22. The study showed that IPZ enhanced radiation induced apoptosis and radiosensitivity in HNSCC cell lines but not HUVEC cells or A549 cells.  In addition, IPZ increased PUMA expression and IPZ or KPNB1 knockdown suppressed radiation induced upregulation of PD-L1 expression.

In general, the study seems to have been well planned and executed. However, a number of improvements / clarifications are required.

The authors show no significant effects in A549 cells, is this because these are derived from adenocarcinoma, why not try a lung SCC derived cell line before concluding this is unique to HNSCC?

Did the authors carry out a clonogenic assay on cells after KPNB1 knockdown? If not, please include an explanation of why this was not included.

More information on radiation dosimetry should be included.

In Figure 1D and F, a plot of surviving fraction should also be included

Figure 1 legend needs to be clearer. Each panel should be described in turn, individually.

It should be clear in the title that this is an in vitro study, ie. not in HNSCC patients but in cell lines

The standard of English needs to be improved throughout the manuscript.

Author Response

We are glad that the reviewer expressed that our study is well-planned and -executed. We appreciate the reviewer’s suggestions and have tried our best to address the reviewer’s comments. All the revisions have been highlighted in the revised manuscript.

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The author has addressed all of my concerns.

Reviewer 2 Report

Thank you to the authors for addressing my comments.

Back to TopTop